Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 7/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674131 | 0.85 | MAPKAPK5 (0.48) | MAPKAPK5KDM4EALDH1A1TTK | |
| SCHEMBL275207 | 0.79 | TTK (0.46) | MAPKAPK5TTKBACE1BACE2 | |
| SCHEMBL1674121 | 0.79 | HDAC1 (0.41) | ALDH1A1 | |
| SCHEMBL1674062 | 0.77 | TP53 (0.48) | MAPKAPK5KDM4ETTK | |
| SCHEMBL1674141 | 0.77 | AURKA (0.44) | MAPKAPK5KDM4EALDH1A1BACE1BACE2 | |
| SCHEMBL1674040 | 0.74 | AURKA (0.47) | MAPKAPK5 | |
| SCHEMBL29106539 | 0.74 | AURKA (0.47) | MAPKAPK5KDM4EALDH1A1TTKBACE1 | |
| SCHEMBL11939502 | 0.74 | BACE1 (0.44) | MAPKAPK5ALDH1A1TTKBACE1BACE2 | |
| SCHEMBL3469708 | 0.73 | TTK (0.52) | TTKBACE1BACE2 | |
| SCHEMBL1674223 | 0.72 | CD38 (0.43) | MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | disclosed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| EP-2027124-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-02-25 | — | — | EP | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885KDM4E 4351/4885ALDH1A1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.